

GPI/645  
TECH CENTER 1600/2900  
RECEIVED  
FEB 04 2002



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Berlin, et al.

Art Unit: 1645

Serial No: 09/517,491

Attorney Docket No. APBI-P06-036

Filed: March 2, 2000

Examiner: Zeman, Robert A.

For: Immunosuppressant Target Proteins

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents Washington, D.C. 20231 on the date indicated below:

December 17, 2001

Date of Signature  
and of Mail Deposit

  
Brent LaBarge

**TRANSMITTAL OF SEQUENCE LISTING IN COMPUTER READABLE FORM**

**IN COMPLIANCE WITH 37 C.F.R. §§1.821(e)**

Box Sequence


**COPY OF PAPERS  
ORIGINALLY FILED**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office communication mailed on November 16, 2001, and in accordance with 37 C.F.R. §1.821(e), the content of the "Sequence Listing" in the above-referenced continuation patent application is identical to the sequence listing filed in the parent application, U.S. Serial No. 08/360,144, filed December 20, 1994. Applicant respectfully requests that a copy of the sequence listing filed in the parent application be included in the above-identified application in lieu of a new C.R.F. No new matter has been added.

Respectfully submitted,  
ROPES AND GRAY

By   
Matthew P. Vincent  
Registration No. 36,709  
Telephone (617) 951-7739  
Facsimile (617) 951-7050

Boston, Massachusetts 02110  
Date: December 17, 2001

JAN 3 0 2002

Application No. 0517,491

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other:

**Applicant Must Provide:**

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216  
For CRF Submission Help, call (703) 308-4212  
PatentIn Software Program Support

Technical Assistance.....703-287-0200  
To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**